The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Reata Announces Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
Apr. 03, 2018 08:54AM PST
Pharmaceutical InvestingReata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced that its licensee, Kyowa Hakko Kirin received designation under the Priority Review and Designation System, or SAKIGAKE Designation, by the Japanese Ministry of Health, Labour and Welfare, for bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease (DKD). As quoted in the press release: The Priority …
Reata Pharmaceuticals (Nasdaq:RETA) a clinical-stage biopharmaceutical company, announced that its licensee, Kyowa Hakko Kirin received designation under the Priority Review and Designation System, or SAKIGAKE Designation, by the Japanese Ministry of Health, Labour and Welfare, for bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease (DKD).
As quoted in the press release:
The Priority Review and Designation System in Japan is designed to accelerate the development of new treatments with the potential to demonstrate significant improvements in efficacy over existing therapies. Designated products are eligible to receive prioritized consultation services and premarket pharmaceutical affairs review by the Japanese regulatory authority.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.